Vol. 7, Issue 1, Part A (2025)

Background: Erectile dysfunction (ED) is a common condition with multifactorial causes, affecting men's quality of life and mental health. Traditional treatments like PDE5 inhibitors and penile implants provide symptomatic relief but do not address the underlying pathology. Recent advances in regenerative medicine have introduced platelet-rich plasma (PRP) as a potential therapy for ED. The rich in growth factors, PRP promotes tissue regeneration, angiogenesis, and endothelial repair. Preclinical and clinical studies suggest PRP may improve erectile function by enhancing penile blood flow and vascular integrity.

Aim of the study: The aim of this study was to assess the effectiveness of platelet-rich plasma (PRP) as a treatment for erectile dysfunction (ED) by evaluating its impact on erectile function over time based on sexual function scores.

Methods: This prospective observational study was conducted on 45 male patients (40-70 years) diagnosed with erectile dysfunction (ED) at Ajoy Joba Shebasram and R. (Private Chamber), Jorakol Bazar, khulna, Bangladesh from January to December 2024. Baseline assessments included demographic, clinical, and metabolic parameters. Participants received structured treatment (lifestyle modifications, pharmacotherapy, or both), with sexual function assessed using the International Index of Erectile Function (IIEF) at baseline and follow-ups (1st, 3rd, and 6th months). Platelet-rich plasma (PRP) was prepared via centrifugation and injected into the corpus cavernosum. Data were analyzed using SPSS v26, with repeated measures of ANOVA assessing IIEF score changes. A p-value <0.05 was considered statistically significant.

Result: The study analyzed a population with a mean age of 56.2 years and a BMI of 26.5 kg/m², with an average erectile dysfunction (ED) of 4.8 years. Hypertension (48.89%) was the most common comorbidity, followed by dyslipidemia (37.78%) and impaired glucose tolerance (26.67%). Significant metabolic abnormalities included elevated triglycerides (37.78%) and low HDL levels (42.22%). Over six months, sexual function improved significantly, with the IIEF-EF score increasing from 13.2 to 23.5 (p<0.001). Other domains, including orgasmic function, sexual desire, satisfaction, and general well-being, also showed statistically significant improvements (p<0.001).

Conclusion: Platelet-rich plasma (PRP) shows promise as a regenerative therapy for erectile dysfunction (ED), significantly improving erectile function, sexual desire, and satisfaction. Increased IIEF scores suggest PRP enhances penile vascularization and endothelial repair, addressing ED’s root causes rather than just symptoms, making it a potential alternative treatment for ED management.